Last reviewed · How we verify
Prednisone and Aspirin
Prednisone suppresses immune and inflammatory responses via glucocorticoid receptor activation, while aspirin inhibits platelet aggregation and reduces inflammation through cyclooxygenase inhibition.
Prednisone suppresses immune and inflammatory responses via glucocorticoid receptor activation, while aspirin inhibits platelet aggregation and reduces inflammation through cyclooxygenase inhibition. Used for Inflammatory and autoimmune conditions requiring corticosteroid therapy with concurrent antiplatelet/anti-inflammatory benefit, Conditions requiring both immunosuppression and thromboprophylaxis.
At a glance
| Generic name | Prednisone and Aspirin |
|---|---|
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | Corticosteroid and nonsteroidal anti-inflammatory drug (NSAID) combination |
| Target | Glucocorticoid receptor (prednisone); Cyclooxygenase-1 and Cyclooxygenase-2 (aspirin) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Prednisone is a corticosteroid that binds glucocorticoid receptors to suppress T-cell activation, cytokine production, and inflammatory mediator release. Aspirin irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis, thereby decreasing platelet aggregation and inflammation. The combination leverages both immunosuppressive and antiplatelet/anti-inflammatory effects.
Approved indications
- Inflammatory and autoimmune conditions requiring corticosteroid therapy with concurrent antiplatelet/anti-inflammatory benefit
- Conditions requiring both immunosuppression and thromboprophylaxis
Common side effects
- Gastrointestinal bleeding or ulceration
- Hyperglycemia
- Immunosuppression/increased infection risk
- Osteoporosis
- Hypertension
- Dyspepsia
Key clinical trials
- Anti-inflammatory Therapy for Recurrent In-stent Restenosis (PHASE4)
- The Clinical Features and Pregnancy Outcomes of CTD Patients
- Treatment and Clinical Outcomes Among SLE Patients in Pregnancy (PHASE1)
- Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center (NA)
- PROUD Study - Preventing Opioid Use Disorders (PHASE4)
- Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
- Effect of Prednisone and Aspirin on IVF-ET Outcome Among Patients With Thyroid Autoimmunity (PHASE4)
- Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: